沙格列扎治疗非酒精性脂肪性肝炎的2期双盲随机对照试验
本研究为在西方人群中开展的2期双盲随机对照试验,旨在评估双重PPARα/γ激动剂沙格列扎对非酒精性脂肪性肝炎(NASH)患者组织学改善的信号。沙格列扎在印度已获批用于治疗NASH,前期研究显示其可改善肝脏组织学,并因其对糖脂代谢的有利影响而具有临床获益潜力。
要点
- 沙格列扎为双重PPARα/γ激动剂,在印度已获批治疗NASH。
- 本研究为2期双盲随机对照试验,在西方NASH人群中验证组织学改善信号。
- 生活方式干预和减重仍是NASH唯一推荐的治疗方式,尚无药物获批。
核心结论
- 沙格列扎在西方NASH患者中是否具有组织学改善信号尚待本研究结果验证。
研究设计与样本
- 2期双盲随机对照试验,在西方人群NASH患者中开展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic steatohepatitis (NASH), the clinically aggressive variant of nonalcoholic fatty liver disease, is characterized by hepatocellular injury and inflammation.1 Patients with NASH are at higher risk of progression to cirrhosis and it is therefore targeted for drug development efforts.2 Lifestyle modifications and weight loss are the only recommended modalities and no drug is yet approved for the treatment of patients with NASH. Saroglitazar is a dual PPAR α/γ agonist, which has shown promise for treatment of nonalcoholic fatty liver disease.3 Because of its combined PPAR-α/γ agonism, it has a clinically favorable impact of glucose and lipid metabolism. Saroglitazar has shown to improve liver-related histology in patients with NASH and was recently approved for treatment of NASH in India.4 The current study builds on the published literature in this proof of concept study to determine if there is a signal for histologic improvement of NASH with saroglitazar in a Western population.
引用
- Siddiqui MS, Idowu MO, Parmar D, et al. A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2020. PMID: 33152542. doi:10.1016/j.cgh.2020.10.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。